Welcome to
SK life science
navigator

Helping patients who are prescribed XCOPRI® (cenobamate tablets) CV get started and continue on therapy as appropriate.

SK life science navigator may assist eligible
patients with the following*:

SK life science navigator
can help patients access XCOPRI® (cenobamate tablets) CV with the following:

Benefits Verification

Determine drug coverage for patients prescribed XCOPRI based on the patient’s individual health plan

Responsive image

Prior Authorization Information

Determine the information that may be necessary to help obtain a PA decision from a patient’s insurer

Responsive image

Patient Assistance Program (PAP)

SK Life Science, Inc., may provide XCOPRI for free to eligible patients who do not have prescription drug or health insurance coverage and who, without assistance, cannot afford XCOPRI

Responsive image

SK Life Science Navigator Enrollment Form

HCP Offices can electronically fill out the Navigator Enrollment Form. Click the link below to get started.

SK Life Science Navigator Enrollment Form

Responsive image

Patient Authorization

You can sign a Patient Authorization for the SK life science navigator electronically. Click "Get Started" below, type in “XCOPRI” and follow the prompts.

Get Started

Responsive image

Patient Assistance Program (PAP) Application

You can fill out and sign the Patient Assistance Program (PAP) Application electronically. Click the link below to get started.

SK Life Science Navigator PAP Application

Always talk to a healthcare provider if there are any questions.

Patients must meet eligibility criteria for PAP, which includes: 1) US resident, 2) on-label diagnosis, 3) meets financial threshold, 4) patient is uninsured, functionally uninsured, or has a financial hardship.

Downloadable Resources

Call for XCOPRI treatment support

Should you need additional information, or to speak to a care coordinator, please call 866-756-2844 (866-SK-NAVIG).

© 2022 SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd.    
PM-US-SKNAG-0030    07/21